Chemical cardiac sympathetic denervation hampers defibrillation in the dog. 1997

R Ruffy, and M Leonard
University of Utah Health Sciences Center, Salt Lake City, USA.

BACKGROUND Cardiac defibrillation is influenced by several physical and nonphysical factors. Previous animal studies have shown that beta-adrenergic stimulation facilitates the process of defibrillation. The purpose of this study was to examine the effects of chemical sympathetic denervation on the ability to defibrillate the canine heart. RESULTS Twelve chronically instrumented dogs underwent serial measurements of the energy required to defibrillate the heart, ten before and after treatment with 50 mg/kg 6-hydroxydopamine (6-OHDA). Two of the animals received 1% ascorbic acid in 0.9% saline solution (the vehicle) only, and three dogs received the vehicle followed several weeks later by 6-OHDA. Following treatment with 6-OHDA, the energy to defibrillate the heart rose from 11.9 +/- 7.4 J (baseline 1) and 14.3 +/- 8.7 J (baseline 2) to 23.3 +/- 10.8 J (P < 0.01 and < 0.05, respectively). In contrast, following saline administration, no significant change was measured in the energy required to defibrillate the heart. After 6-OHDA, 5 of the 10 animals could not be defibrillated versus none of 5 after saline treatment (Chi square 3.750, P = 0.053). In surviving animals, a return of measurements to, or toward, baseline was measured after active treatment. CONCLUSIONS In this chronically instrumented, closed chest animal model, chemical sympathetic denervation with 6-OHDA hampered the process of cardiac defibrillation. These results support previous observations of a modulating effect of this process by adrenergic activity.

UI MeSH Term Description Entries
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004554 Electric Countershock An electrical current applied to the HEART to terminate a CARDIAC ARRHYTHMIA. Cardiac Electroversion,Cardioversion,Defibrillation, Electric,Electroversion, Cardiac,Electrical Cardioversion,Electroversion Therapy,Therapy, Electroversion,Cardiac Electroversions,Cardioversion, Electrical,Cardioversions,Cardioversions, Electrical,Countershock, Electric,Countershocks, Electric,Defibrillations, Electric,Electric Countershocks,Electric Defibrillation,Electric Defibrillations,Electrical Cardioversions,Electroversion Therapies,Electroversions, Cardiac,Therapies, Electroversion
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006329 Heart Conduction System An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart. Conduction System, Heart,Conduction Systems, Heart,Heart Conduction Systems,System, Heart Conduction,Systems, Heart Conduction
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013563 Sympathectomy, Chemical Sympathectomy using chemicals (e.g., 6-hydroxydopamine or guanethidine) which selectively and reversibly destroy adrenergic nerve endings while leaving cholinergic nerve endings intact. Chemosympathectomy,Denervation, Sympathetic, Chemical,Chemical Sympathectomy,Chemical Sympathetic Denervation,Sympathetic Denervation, Chemical,Chemical Sympathectomies,Chemical Sympathetic Denervations,Chemosympathectomies,Denervation, Chemical Sympathetic,Denervations, Chemical Sympathetic,Sympathectomies, Chemical,Sympathetic Denervations, Chemical
D016627 Oxidopamine A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals. 6-Hydroxydopamine,6-OHDA,Oxidopamine Hydrobromide,Oxidopamine Hydrochloride,6 Hydroxydopamine,Hydrobromide, Oxidopamine,Hydrochloride, Oxidopamine

Related Publications

R Ruffy, and M Leonard
June 2001, Clinical nuclear medicine,
R Ruffy, and M Leonard
June 1992, Canadian journal of physiology and pharmacology,
R Ruffy, and M Leonard
October 1992, Biulleten' eksperimental'noi biologii i meditsiny,
R Ruffy, and M Leonard
September 2000, Annals of internal medicine,
R Ruffy, and M Leonard
March 2014, Heart rhythm,
R Ruffy, and M Leonard
December 1986, Naunyn-Schmiedeberg's archives of pharmacology,
R Ruffy, and M Leonard
January 2020, Indian pacing and electrophysiology journal,
R Ruffy, and M Leonard
May 2021, Autonomic neuroscience : basic & clinical,
R Ruffy, and M Leonard
June 2022, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Copied contents to your clipboard!